Based on these findings, we expanded the number of neuroendocrine tumours examined and evaluated GPER expression in a broad panel of bronchopulmonary (BP-NENs) and gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) of different origins. Here, GPER1 is linked to neuroendocrine neoplasm.